A retrospective analysis was conducted to examine factors affecting early mortality after myeloablative, single-unit cord blood transplantation (CBT) for hematological malignancies in adolescents and adults. Data were collected from the three main CBT registries pooling 514 records of unrelated, single, unmanipulated, first myeloablative allogeneic CBTs conducted in North America or Europe from 1995 to 2005, with an HLA match X4/6 loci, in patients aged 12-55. Overall 100-day, 180-day and 1-year survival (Kaplan-Meier method) were 56, 46 and 37%, respectively, with no significant heterogeneity across registries. Multivariate analysis showed cell dose o2.5 Â 10 7 /kg (odds ratio (OR) 2.76, Po0.0001), older age (P ¼ 0.002), advanced disease (P ¼ 0.02), positive CMV sero-status (OR 1.37 P ¼ 0.11), female gender (OR 1.43, P ¼ 0.07) and limited CBT center experience (o10 records contributed, OR 2.08, P ¼ 0.0003) to be associated with higher 100-day mortality. A multivariate model predictive of 1-year mortality included similar prognostic factors except female gender. Transplant year did not appear as a significant independent predictor. This is the first analysis to pool records from three major CBT registries in the United States and Europe. In spite of some differences in practice patterns, survival was remarkably homogeneous. The resulting model may contribute to better understanding factors affecting CBT outcomes.
Introduction
Allogeneic hematopoietic SCT (HSCT) is a curative procedure for several hematopoietic malignancies. However, wide application of this procedure is limited by the availability of a suitably HLA-matched donor. 1 Recent studies have shown that the clinical outcomes after umbilical cord blood transplantation (CBT) are comparable to outcomes after transplantation from an HLA-matched unrelated marrow donor, provided that a sufficient cell dose per body weight is infused. [1] [2] [3] Consequently, cord blood is increasingly used as an alternative hematopoietic stem cell source, to date it is estimated that more than 20 000 CBTs have been conducted, of which almost half were in adults. 4, 5 Very few of these transplantations were carried out as part of randomized controlled trials and assessment of outcomes of CBT in adults to date is based predominantly on case series and registry analyses. [1] [2] [3] [4] [5] In this study, we describe a pooled analysis of a historical cohort compiled from three outcome registries: the Center for International Blood and Marrow Transplant Research (CIBMTR), 6, 7 the New York Blood Center National Cord Blood Program (NYBC) 7 and Eurocord-Netcord 4 registry. The objective of the pooled analysis was to identify factors affecting mortality in this population based on multivariate prognostic models for mortality. These models may provide insights into the relative importance of various prognostic factors for outcomes and consequently, may facilitate the comparison of clinical outcomes between series with different patient case-mixes.
Materials and methods

Pooling registry data
Records for unrelated CBTs carried out with myeloablative conditioning and with a single unmanipulated cord blood unit (CBU) in the years 1995 to 2005 were provided to the data-management center at Gertner Institute for Epidemiology and Health Policy Research by the three outcome registries: CIBMTR, NYBC and Eurocord. Records were included in the pooled analysis only if they met the following eligibility criteria: age 12-55 years; transplantation for acute leukemia (unless documented refractory disease), CML in chronic or accelerated phase, Hodgkin lymphoma or non-Hodgkin lymphoma in relapse or, myelodysplastic syndrome; no previous allogeneic transplantation; myeloablative conditioning regimen; single, unmanipulated CBU; with HLA disparity p2/6 loci was defined according to the total number of Ag mismatches at HLA-A and HLA-B loci (defined by serologic or low-tointermediate-resolution DNA typing) and the number of allele mismatches at HLA-DRB1; CBU cryopreserved cell dose X1 Â 10
7
. Total nucleated cells/kg body weight; transplant year 1995 to 2005; North American or European transplant center; availability of 100-day vital status. After three data sets were merged by the data management center into a single, final data set, logical checks were applied to confirm the integrity and consistency of the pooled data and any discrepancies were resolved. To achieve consistency across registries, several variables were re-coded. Transplant centers CBT experience was classified as 'novice' (o10 patients registered in the database) or 'experienced' (10 or more patients). In Eurocord, often only infused cell dose or cell dose at collection were captured, and crypreserved dose was estimated as 123 and 85% of the latter, respectively, based reports comparing these values. [8] [9] [10] [11] [12] [13] [14] Duplicate records were identified based on date of birth, sex, disease, date of transplant and transplant center, and HLA.
Statistical methods
The outcomes for the main analysis were chosen to be the 100-day and 1-year mortality rates. In addition, the 180-day mortality, engraftment failure (surviving to day 42 but not achieving X500 neutrophils/mm 3 by that day) and acute GVHD rates were examined descriptively. The risk factors for mortality that were analyzed included patient demographics, disease characteristics (for example, type of hematological malignancy and disease status), treatment and transplant details, registry, year of transplant (1995-1997, 1998-2001 and 2002-2005) and transplant center CBT experience.
Survival curves were estimated using the Kaplan-Meier method 15 and Greenwood's formula for s.e. 16 Heterogeneity across registries was assessed using w 2 -tests for categorical variables and the log-rank test for survival. 17 Logistic regression was used to build the prognostic model for 100-day and for 1-year mortality. 18 The model was built in three stages. First, we entered five 'established' prognostic factors, associated with CBT mortality in previous publications (patient per CBU HLA disparityzero, one or two mismatches for up to six Ags per alleles at the three loci; 7, 19, 20 cryopreserved cell dose-o or 42. 1, 20, 23, 24 and CMV sero-status-positive or negative 1 ) into a backward stepwise procedure. The resultant model was defined as the 'basic' prognostic model. Second, eight 'exploratory' prognostic factors, with less compelling evidence for association with mortality (sex, time since diagnosis, donor-recipient ABO mismatch, previous autologous transplant, donor-recipient sex mismatch, myeloablative regimen and GVHD prophylaxis regimen and transplant center CBT experience) were added to the basic prognostic model using a forward stepwise procedure. Third, the resulting model was used to check on the potential confounding variables, registry and year of transplant, again using a forward stepwise procedure. At all stages, the critical P-value was 0.05.
Missing values were found for two important explanatory variables, CMV sero-status (16 patients) and transplant center CBT experience (26 patients). In contrast, for the 1-year mortality logistic regression analysis, 30 patients (6%) had survival times censored between 100 days and 1-year. These missing values were handled by multiple imputation. 25 
Results
Study population
In total, 742 records were provided by the 3 registries (after exclusion of 19 duplicate records), 514 of which were found to meet the study eligibility predetermined criteria and were included in the final analysis. Hematological malignancies included ALL (211), AML (144), CML (106), myelodysplastic syndrome (45), Hodgkin lymphoma (2) and nonHodgkin lymphoma (6) . Reasons for exclusion (not mutually exclusive) were non-eligible disease stage (129), unavailable 100-day vital status (49), non-myeloablative conditioning (17) , year of transplant o1995 (1), CBU criteria (manipulation or cell dose) (21) and non-eligible country (56).
Heterogeneity in prognostic factors was found in HLA mismatch, previous autologous transplant, myeloablative regimen, GVHD prophylaxis, transplant center experience and year of transplant. These differences are likely to reflect the differing histories of the registries and the differing clinical management policies across the transplant centers, rather than artifacts arising from differences in data reporting or processing. Mortality rates over 1 year were similar across the three registries ( Figure 1 ). In all, 227 patients (44%) of the 514 died within 100 days of the transplant. Mortality increased to 54% (276 deaths) and 63% (319 deaths) after 180 days and 1 year, respectively. Overall 100-day, 180-day and 1-year survival (KaplanMeier method) were 56, 46 and 37%, respectively, with no significant heterogeneity across registries. Reported 100-day, 180-day and 1-year disease-free survival (KaplanMeier method) were 54, 42 and 33%, respectively. Eightyone (17%) patients had engraftment failure; 177 (36%) had acute GVHD grade II-IV. Engraftment failure rates and acute GVHD disease rates were also similar across registries ( Figure 1) .
In a univariate analysis (Table 1) , four of the five 'established' prognostic factors were significantly related to mortality at 100 days and 1 year. Of the eight 'exploratory' prognostic factors, transplant center CBT experience was significantly related to both 100-day and 1-year mortality, while sex appeared related to 100-day mortality only. Among potential confounding factors, year of transplant appeared to be related to mortality. It is noteworthy that the proportion of patients with cell dose o2.5 Â 10 7 /kg (associated with poor prognosis), 7, 20, 21 declined sharply over these years, being 67, 54 and 24% in 1995-1997, 1998-2001 and 2002-2005 , respectively (data not shown). The multivariate model for 100-day mortality included all of the above factors except for year of transplant, which was no longer significant after cell dose was included in the model ( Table 2 ). The most influential factors were cell dose, age and center experience. The multivariate model for 1-year mortality included CMV sero-status, cell dose, disease status, patient age and center experience.
Discussion
This analysis pooled together records of unrelated single unmanipulated CBTs in adults and adolescents from the three major international CBT registries, and was aimed to identify prognostic factors associated with CBT outcomes. This may provide insights into the effects of patient casemix on clinical outcome and support patient risk assessment. This is of particular importance in adult CBT research, considering the inherent challenges that limit the conduct of large randomized controlled trials in this field. To the best of our knowledge, this is the largest cohort of adults with CBT in North America and Europe that has been reported to date and the first to pool records from all three registries. The crude overall and disease-free survival outcomes are comparable to those reported previously in cord blood registry reports of single, myeloablative CBT in North America and Europe. 4, 5 TRM is inferior to results in Japanese studies, 3 it has been speculated to results from availability of higher cell dose units, preferential racial genetic homogeneity and possibly some differences in GVHD prophylaxis.
Several published analyses have previously investigated factors affecting CBT clinical outcomes. 1, 2, 7, [19] [20] [21] [22] [23] [24] 26, 27 Many of these studies focused on a predominantly pediatric population 20, [22] [23] [24] 27 and analyzed treatment-related mortality or EFS rather than overall mortality. Some of the studies with an adult population were relatively small, 19, 23 or focused on comparison with BM transplant. 1 As has been widely recognized in previous work, 7,20-22 we found low cell dose to be strongly associated with increased overall mortality. Using a cut-point of 2.5 Â 10 7 cells/kg to model this effect captured most of the relationship. We also confirmed previous reports of advanced disease stage 1, 20, 22 and CMV seropositivity 1 associated with worse survival. A majority of the reports 7, [19] [20] [21] 24, 27 found greater HLA discrepancy is related with higher treatment-related mortality or reduced EFS. Conversely, and similar to our findings, Arcese et al. 23 did not observe an effect of HLA discrepancy on mortality. A possible explanation for our not finding HLA discrepancy to be predictive of mortality is that there exists a trade-off in the CBU selection process between cell dose and HLA disparity (that is, smaller units more 'acceptable' with lesser HLA disparity). Another explanation could be that HLA matching has limited effect in patients who receive relatively low cell dose, as these patients may die early because of infections, regardless to HLA effect. Indeed our pooled cohort, 50% of the transplants involved cell dose below 2.5 Â 10 7 /kg total nucleated cells; however, the test for an interaction term between these two variables was negative. Among the 'exploratory' factors analyzed, only female sex was found to be weakly associated with survival at 100 days. It was not predictive at 1 year. Female sex has been previously described 23 as a negative prognostic factor by one group. Transplant center CBT experience ('center effect'), was significantly related to survival outcomes at 100 days and at 1-year and was therefore included in the final logistic models. Center effect has previously been shown in some reports 20 but not in others. 24 The number of records contributed to the cohort by each transplant center was used as a surrogate measure for the transplant center's CBT experience. We selected the median number of records as the threshold, defining experienced centers as those contributing 10 or more records, and novice centers as those contributing o10 records. Sensitivity analysis showed that this cutoff yielded the strongest association with outcomes (data not shown). This may reflect the effect of center experience on patient selection and/or transplant management. An alternative explanation is that centers with initial poor outcomes abandoned CBT, and thus remained with lesser experience.
Finally, we tested two potential confounders: registry and year of transplant. The three registries varied with regards to their data capture procedures; nevertheless, all incorporated a structured review process and provided sufficiently detailed data, enabling the application of uniform eligibility criteria at a patient record level. Some variations in practice patterns among centers reporting to the three registries were shown, yet in spite of these variations, remarkable homogeneity in mortality outcomes of across registries, up to 1-year post transplantation was shown: 42, 45 and 43% at 100 days and 59, 65 and 63% at 1-year, for CIBMTR, NYBC and Eurocord, respectively. With regards to the year of transplant, the 100-day mortality rate was 57% in patients treated in 1995-1997, 42% in those treated in 1998-2001, and 37% in those treated in 2002-2005 (w 2 on 2 degrees of freedom ¼ 10.4, P ¼ 0.006). A similar pattern was observed in the 1-year survival outcomes. On further inspection we found that the proportion of patients transplanted with cell dose o2.5 Â 10 7 /kg also declined sharply over these years, being 66, 50 and 21% in 1995-1997, 1998-2001 and 2002-2005, respectively. This may well reflect the emerging recognition among the medical community of the negative effect of low cell dose in the cord blood graft on the clinical outcomes of CBT. Hence, when we added year of transplant to the 'basic' prognostic model, the relationship was no longer statistically significant. The test for trend over the three time periods was also not significant. We also found some indication of improved patient selection over time, thus, the proportion of patients transplanted with relapsed leukemia was 26% in 1995-1997, 18% in 1998-2001 and 15% in 2002-2005 . These findings support the notion that the observed improvement in CBT outcomes over time in our cohort is attributable predominantly to better patient and CBU selection.
This analysis has several potential limitations: as in any observational study, additional potential unmeasured confounders may exist, for example, cord blood bank, age of the CBU or storage conditions. Data regarding myeloablative conditioning were incomplete. Although the three registries include much of the western world's experience in single-unit CBT within the defined age group and geographic regions, selection bias and reporting bias may not be completely excluded. Thus, CIBMTR have almost complete 3-month follow-up, NYBC has 90-95% and Eurocord reports 80% 3-month follow-up. At the time the cohort was assembled (2005) some of the follow-up data from the most recent years was still unavailable to the registry. Even when 3-month follow-up was available, some records had missing data. The numbers of patients with lymphoma, those who received previous autologous transplants, fludarabine for conditioning were small and, consequently, we had limited power to detect an effect of those variables. As the registries varied with regards to their data structure and definitions, particular efforts were directed toward aligning the data to enable an accurate and valid merge. The relatively high proportion of patients with CML in this analysis (20%) reflect management patterns at the time the registry, and are similar to the findings of Laughlin et al. 5 Estimation of cryopreserved cell dose from the infused dose or the dose at collection was a particular challenge and no doubt introduced inaccuracies. Indeed, when analyzing by registry, cell dose was significantly related to 100-day mortality in CIBMTR (OR 2.6, 95% confidence interval 1.04-6.5) and NYBC (OR 3.65, 95% confidence interval 2.19-6.06), but failed to reach significance in Eurocord (OR 1.58; 95% confidence interval 0.85-2.93). Data reporting was supported by experienced CBT physicians, and registries were queried in cases of inconsistency or lack of data, yet some inaccuracies may have occurred. Current efforts to harmonize forms across registries will facilitate such analyses in the future. Overall mortality was selected as the outcome variable rather than treatment-related mortality, although the latter accounts for a large proportion of the mortality. The mortality because of disease recurrence may in part be attributable to the cord blood GVL effect and to the transplant regimen. Therefore, we considered overall mortality as the CBT outcome with the greatest clinical significance. Finally, our analysis is limited to single myeloablative un-manipulated CBT. Novel strategies such as double CBT [28] [29] [30] and ex vivo cord blood expansion 31, 32 continue to be analyzed and may enable to broaden the use of CBT in adults and adolescents. Analyses such as the one presented in this paper could help estimating the contribution such interventions, based on a retrospective case-mix adjusted comparison with single CBT outcomes. This may be of particular importance because the assignment of patients to a low dose single CBU transplant in a randomized controlled trial setting would now days be unacceptable, for ethical reasons.
In conclusion, this is the first analysis to pool records from the three major CBT registries in the United States and Europe, which arguably contain much of the world's experience in adult single-unit CBT. In spite of some differences in practice patterns, survival data showed remarkable homogeneity. The findings suggest that the improvement over time in CBT outcomes may be attributable to better patient and CBU selection. This analysis establishes a mechanism for evaluating improvements in CBTs by future interventions.
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